These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33759619)

  • 1. Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant.
    Johnston JP; Cohen EA; Casal GH; Asch WS; Reardon DP
    J Pharm Pract; 2022 Oct; 35(5):701-706. PubMed ID: 33759619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
    Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
    Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation.
    Mimura A; Yamaori S; Ikemura N; Katsuyama Y; Matsuzawa N; Ohmori S
    J Clin Pharm Ther; 2019 Aug; 44(4):565-571. PubMed ID: 30950099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
    Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
    Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time?
    Falconer SJ; Peagam WR; Oniscu GC
    Transplant Proc; 2015; 47(6):1741-5. PubMed ID: 26293044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
    Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
    Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
    Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
    Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A; Iwai T; Uchida J
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients.
    Krzyżowska K; Kolonko A; Giza P; Chudek J; Więcek A
    Transplant Proc; 2018; 50(6):1755-1759. PubMed ID: 30056895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
    Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
    Peksa GD; Schultz K; Fung HC
    J Oncol Pharm Pract; 2015 Dec; 21(6):409-15. PubMed ID: 24938293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.